Recently, the combination of the OX40 antibody and CpG has a remarkable antitumor effect in situ [50], but the drawbacks of in situ immunization are the appropriate immune cells infiltration and adequate tumor injection site. The gene discussed is TNFRSF4; the disease is neoplasm.